What the FDA labels say about taking them together
Gemfibrozil and paclitaxel
Gemfibrozil's FDA label of April 10, 2026 names paclitaxel in its drug interactions section, and paclitaxel's label names gemfibrozil too. The gemfibrozil label: “(C) CYP2C8 Substrates: Gemfibrozil is a strong inhibitor of CYP2C8 and may increase exposure of drugs mainly metabolized by CYP2C8.”
Check it at the source: the gemfibrozil FDA label on DailyMed (effective April 10, 2026, Northstar RxLLC); the paclitaxel FDA label on DailyMed (effective January 21, 2026, Natco Pharma USA LLC).
What does the gemfibrozil label say about paclitaxel?
Gemfibrozil label, drug interactions(C) CYP2C8 Substrates: Gemfibrozil is a strong inhibitor of CYP2C8 and may increase exposure of drugs mainly metabolized by CYP2C8 (e.g., dabrafenib, enzalutamide, loperamide, montelukast, paclitaxel, pioglitazone, rosiglitazone).
Source: FDA drug label (Gemfibrozil), Northstar RxLLC, effective April 10, 2026 (SPL set 75cac02c-56e3-4dfe-b1e2-4ce166b28833), via openFDA; the full label on DailyMed
What does the paclitaxel label say about gemfibrozil?
Paclitaxel label, drug interactionsCaution should be exercised when paclitaxel is concomitantly administered with known substrates (eg, midazolam, buspirone, felodipine, lovastatin, eletriptan, sildenafil, simvastatin, and triazolam), inhibitors (eg, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin), and inducers (eg, rifampin and carbamazepine) of CYP3A4. ( See CLINICAL PHARMACOLOGY section. ) Caution should also be exercised when paclitaxel is concomitantly administered with known substrates (eg, repaglinide and rosiglitazone), inhibitors (eg, gemfibrozil), and inducers (eg, rifampin) of CYP2C8. ( See CLINICAL PHARMACOLOGY. …
Source: FDA drug label (Paclitaxel), Natco Pharma USA LLC, effective January 21, 2026 (SPL set a1eb16b4-285b-4e81-9c4e-1244d4a52af8), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Gemfibrozil | Paclitaxel | |
|---|---|---|
| Labeled for | High cholesterol, Heart attack and coronary artery disease | Breast cancer, Lung cancer |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.104 per tablet 600 mg tablet | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once